How to Help Your Patients Find Spinraza (Nusinersen) in Stock: A Provider's Guide

For SMA specialists and the broader care team, helping patients access Spinraza (nusinersen) is often one of the most labor-intensive parts of managing this disease. The drug's $125,000-per-injection list price, mandatory prior authorization requirements, and specialty distribution model mean that getting a patient their first — or next — dose requires coordinating across multiple systems simultaneously.

This practical guide is designed to help your practice streamline the access pathway for Spinraza-treated patients in 2026.

Understanding the Spinraza Distribution Model

Unlike most specialty biologics, Spinraza is not available at retail or mail-order pharmacies. It is distributed exclusively through specialty pharmacies that ship directly to the treatment facility — typically a hospital or outpatient neurology/neuromuscular clinic. The drug never passes through the patient's hands.

This distribution model means your facility must have an established relationship with a specialty pharmacy authorized to distribute Spinraza, as well as protocols for receiving and storing the drug (refrigerated, 2-8°C, protected from light) and administering it under appropriate conditions.

Step 1: Start Prior Authorization at Diagnosis — Don't Wait

One of the most impactful things your practice can do is initiate the prior authorization process as soon as the treatment decision is made. PA approval typically takes 2 to 4 weeks, and for infantile-onset SMA, delays of this duration can have significant clinical consequences.

To optimize first-pass PA approval rates, ensure your submission includes:

Genetic confirmation of 5q SMA with SMN1 deletion or mutation documentation

SMN2 copy number documentation

SMA type classification (Type 1, 2, 3, or 4) and symptom onset documentation

Baseline functional status (validated scale appropriate to age: CHOP-INTEND, HFMSE, RULM, or HINE-2)

Baseline labs: platelet count, coagulation studies (PT, PTT), and urine protein

Prescriber specialty and facility qualifications for intrathecal drug administration

Step 2: Enroll Every Patient in Biogen's SMA360° Program

Biogen's SMA360° patient support program is one of the most comprehensive in the rare disease space. It provides dedicated case managers who work directly with your practice to:

Verify insurance benefits and identify coverage gaps

Assist with prior authorization submissions and appeals

Coordinate specialty pharmacy ordering and delivery to your facility

Enroll patients in co-pay assistance (for commercially insured patients) or patient assistance programs (for uninsured/underinsured patients)

Provide bridge program access while awaiting PA approval — eligible patients may receive doses at no cost during the authorization review period

Contact SMA360°: 844-477-4672 or spinraza.com. Most SMA care centers have an established account manager with SMA360° — if you don't, establishing this relationship is one of the highest-leverage actions your practice can take.

Step 3: Plan Dosing Logistics Well in Advance

Spinraza injections require significant preparation. Best practices to minimize same-day logistical problems:

Order drug through specialty pharmacy at least 2 weeks before planned dose date to ensure timely delivery

Confirm PA renewal is in place before each dose — some insurers approve only one dose at a time, and expired authorizations can delay treatment

Schedule pre-procedure labs (platelets, coagulation studies, urine protein) at least 1 week before the planned injection date

Ensure imaging guidance (ultrasound or fluoroscopy) is available for young patients or those with spinal abnormalities

Schedule anesthesia support for young infants or patients who require sedation for the procedure

Step 4: Help Patients Navigate the New High-Dose Option

With the March 2026 FDA approval of the High Dose Regimen, providers should proactively counsel patients and families on this new option. For patients on low-dose Spinraza who have plateaued, the transition to high-dose is a clinical conversation worth initiating. Note that insurer coverage policies for the high-dose regimen are still being developed — early PA submissions may require additional clinical justification.

Step 5: Document Functional Outcomes at Every Visit

Insurer renewals increasingly require demonstration of clinical benefit. Consistent documentation of functional outcomes at each visit using validated scales (CHOP-INTEND, HFMSE, RULM) is essential both for clinical management and for supporting PA renewals. Even stable scores (plateaued function rather than progressive decline) can support medical necessity arguments.

How medfinder Supports Provider Practices

medfinder is a paid service that helps practices reduce the time they spend on specialty drug access logistics. By referring SMA patients to medfinder for providers, your team can offload the work of locating specialty pharmacies, verifying drug availability, and coordinating the access process — keeping your clinical staff focused on patient care.

Also see: Spinraza Access Update: What Providers Need to Know in 2026 for clinical updates on the new high-dose regimen and evolving insurer policies.